Skip to main content

Published locations for FDA advisory panel decides tivozanib falls short for advanced renal cell carcinoma

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA advisory panel decides tivozanib falls short for advanced renal cell carcinoma

User login

  • Reset your password
  • /content/fda-advisory-panel-decides-tivozanib-falls-short-advanced-renal-cell-carcinoma
  • /internalmedicinenews/article/58643/oncology/fda-advisory-panel-decides-tivozanib-falls-short
  • /acssurgerynews/article/58643/oncology/fda-advisory-panel-decides-tivozanib-falls-short-advanced
  • /oncologypractice/article/58643/oncology/fda-advisory-panel-decides-tivozanib-falls-short-advanced
  • /hematology-oncology/article/58643/oncology/fda-advisory-panel-decides-tivozanib-falls-short-advanced
  • /internalmedicine/article/58643/oncology/fda-advisory-panel-decides-tivozanib-falls-short-advanced
  • /surgery/article/58643/oncology/fda-advisory-panel-decides-tivozanib-falls-short-advanced-renal-cell